Damora Therapeutics is trading 5.3% higher at $34.74 after HC Wainwright reiterated its Buy rating and $45 price target, highlighting significant upside potential from current levels.
- HC Wainwright's reiteration underscores confidence in the company's valuation, with the $45 target implying substantial growth compared to the current share price.
- The stock's advance comes amid a generally positive market backdrop, as major U.S. indices trade higher, boosting risk appetite for biotech names.